Literature DB >> 21514009

Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease.

Federica Giambattistelli1, Serena Bucossi, Carlo Salustri, Valentina Panetta, Stefania Mariani, Mariacristina Siotto, Mariacarla Ventriglia, Fabrizio Vernieri, Maria Luisa Dell'acqua, Emanuele Cassetta, Paolo Maria Rossini, Rosanna Squitti.   

Abstract

It is now accepted that transition metals, such as iron and copper, are involved in the pathogenesis of the Alzheimer's disease (AD) through their participation in toxic oxidative phenomena. In this context, hemochromatosis (Hfe) and transferrin (Tf) genes are of particular importance, since they play a key role in iron homeostasis. Also, signs of liver distress which accompany metal dysmetabolisms have been shown to be linked to AD. In order to investigate whether and how all these factors are interconnected, in this study we have explored the relationship of the gene variants of Hfe H63D and C282Y and of Tf C2 with serum markers of iron status (iron, ferritin, TF, TF-saturation, ceruloplasmin -CP-, CP and TF serum concentrations (CP/TF) ratio), and of liver function (albumin, transaminases, prothrombin time-prothrombin time (PT)) in a sample of 160 AD patients and 79 healthy elderly controls. Albumin resulted in lower, PT longer and AST/ALT higher ratios in AD patients than in controls, indicating a distress of the liver. Also TF was lower and ferritin higher in AD. Multiple logistic regression backward analyses, performed to evaluate the effects of our biochemical variables upon the probability of developing AD, revealed that a one-unit TF serum-decrease increases the probability of AD by 80%, a one-unit albumin serum-decrease reduces this probability by 20%, and a one-unit increase of AST/ALT ratio generates a 4-fold probability increase. Patients who were carriers of the H63D mutation showed higher levels of iron, lower levels of TF and CP and higher CP/TF ratios, a panel resembling hemochromatosis. This picture was found neither in H63D non-carrier patients, nor in healthy controls. Our results suggest the existence of a link between Hfe mutations and iron abnormalities that increases the probability of developing AD when accompanied by a distress of the liver.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21514009     DOI: 10.1016/j.neurobiolaging.2011.03.005

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  27 in total

1.  DES-Mutation: System for Exploring Links of Mutations and Diseases.

Authors:  Vasiliki Kordopati; Adil Salhi; Rozaimi Razali; Aleksandar Radovanovic; Faroug Tifratene; Mahmut Uludag; Yu Li; Ameerah Bokhari; Ahdab AlSaieedi; Arwa Bin Raies; Christophe Van Neste; Magbubah Essack; Vladimir B Bajic
Journal:  Sci Rep       Date:  2018-09-06       Impact factor: 4.379

Review 2.  Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.

Authors:  Suzanne M de la Monte
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 3.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

4.  The characteristics of transferrin variants by carbohydrate-deficient transferrin tests using capillary zone electrophoresis.

Authors:  Gilsung Yoo; Juwon Kim; Kap Joon Yoon; Jong-Han Lee
Journal:  J Clin Lab Anal       Date:  2018-04-17       Impact factor: 2.352

5.  Brain structure in healthy adults is related to serum transferrin and the H63D polymorphism in the HFE gene.

Authors:  Neda Jahanshad; Omid Kohannim; Derrek P Hibar; Jason L Stein; Katie L McMahon; Greig I de Zubicaray; Sarah E Medland; Grant W Montgomery; John B Whitfield; Nicholas G Martin; Margaret J Wright; Arthur W Toga; Paul M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-09       Impact factor: 11.205

6.  ATP7B variants as modulators of copper dyshomeostasis in Alzheimer's disease.

Authors:  Rosanna Squitti; Renato Polimanti; Mariacristina Siotto; Serena Bucossi; Mariacarla Ventriglia; Stefania Mariani; Fabrizio Vernieri; Federica Scrascia; Laura Trotta; Paolo Maria Rossini
Journal:  Neuromolecular Med       Date:  2013-06-13       Impact factor: 3.843

Review 7.  Neuroimaging and genetic risk for Alzheimer's disease and addiction-related degenerative brain disorders.

Authors:  Florence F Roussotte; Madelaine Daianu; Neda Jahanshad; Cassandra D Leonardo; Paul M Thompson
Journal:  Brain Imaging Behav       Date:  2014-06       Impact factor: 3.978

8.  Linkage disequilibrium and haplotype analysis of the ATP7B gene in Alzheimer's disease.

Authors:  Rosanna Squitti; Renato Polimanti; Serena Bucossi; Mariacarla Ventriglia; Stefania Mariani; Dario Manfellotto; Fabrizio Vernieri; Emanuele Cassetta; Francesca Ursini; Paolo Maria Rossini
Journal:  Rejuvenation Res       Date:  2013-02       Impact factor: 4.663

Review 9.  Alteration of Iron Concentration in Alzheimer's Disease as a Possible Diagnostic Biomarker Unveiling Ferroptosis.

Authors:  Eleonora Ficiarà; Zunaira Munir; Silvia Boschi; Maria Eugenia Caligiuri; Caterina Guiot
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

10.  The clinical use of blood-test factors for Alzheimer's disease: improving the prediction of cerebral amyloid deposition by the QPLEXTM Alz plus assay kit.

Authors:  Haeng Jun Kim; Jong-Chan Park; Keum Sim Jung; Jiyeong Kim; Ji Sung Jang; Sunghoon Kwon; Min Soo Byun; Dahyun Yi; Gihwan Byeon; Gijung Jung; Yu Kyeong Kim; Dong Young Lee; Sun-Ho Han; Inhee Mook-Jung
Journal:  Exp Mol Med       Date:  2021-06-09       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.